Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.35 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 8/20 | 0.34 |
| ▸ | HTR1B | P28222 | 7/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28783376 | 0.67 | MAPKAPK2 (0.40) | MAPKAPK2AHRPARP1 | |
| SCHEMBL28783427 | 0.67 | MAPKAPK2 (0.34) | MAPKAPK2 | |
| SCHEMBL22814374 | 0.66 | — | — | |
| SCHEMBL22798664 | 0.66 | CA1 (0.37) | MAPKAPK2AHR | |
| SCHEMBL24240924 | 0.66 | HTR2C (0.33) | HTR1D | |
| SCHEMBL2263042 | 0.66 | HTR2A (0.35) | LRRK2 | |
| SCHEMBL2398840 | 0.65 | AHR (0.52) | HTR1DHTR1BAHRPARP1PIK3CD | |
| SCHEMBL21237266 | 0.64 | CA2 (0.38) | — | |
| SCHEMBL20863779 | 0.64 | ADRB1 (0.31) | HTR1DHTR1B | |
| SCHEMBL16685040 | 0.63 | HTR2C (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11364303-B2 | Cysteine engineered antibody drug conjugates | PFIZER INC. (US) | 2022-06-21 | — | — | US | disclosed |
| US-20190099499-A1 | CYSTEINE ENGINEERED ANTIBODY DRUG CONJUGATES | PFIZER (US) | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11364303-B2 | Cysteine engineered antibody drug conjugates | LNPEP, CTH, DNPEP | MAPKAPK2 4070/4885BRD9 1676/4885HTR1D 4755/4885 |
| US-20190099499-A1 | CYSTEINE ENGINEERED ANTIBODY DRUG CONJUGATES | LNPEP, CTH, DNPEP | MAPKAPK2 4070/4885BRD9 1676/4885HTR1D 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.